First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy

A recent post hoc analysis of the CheckMate 214 trial looked at the nivolumab plus ipilimumab combination in 108 patients with advanced renal cell carcinoma (RCC) who had not had surgery to remove their cancer (nephrectomy). Patients were randomised to nivolumab plus ipilimumab every 3 weeks followed by nivolumab alone (53 patients) or sunitinib every […]

read more

Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. Also, patients with brain metastases from RCC are not allowed in most clinical trials, and there is an unmet need for treatment of […]

read more

Survival after nephrectomy for various kidney cancer subtypes

Data presented at the American Urological Association (AUA) 2021 meeting last month shows that 5-year survival rates following partial or radical nephrectomy for renal cell carcinoma (RCC) vary depending on the histology of the RCC subtype. The results of this study have implications for developing personalised therapies to target high-risk, aggressive tumours. The researchers identified […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

Role of nephrectomy for metastatic kidney cancer in the immunotherapy era

Three phase III clinical trials (Keynote 426, Checkmate 9ER and Checkmate 214) assessing first-line treatment with immunotherapy in metastatic renal cell carcinoma (RCC) compared to sunitinib were analysed for patients who had prior nephrectomy compared to those who did not. Patients who had prior nephrectomy had a longer time before the immunotherapy stopped working and […]

read more

Potential biomarker to predict risk of recurrence after nephrectomy for locally advanced kidney cancer

Currently, the search for a reliable biomarker to identify those patients who are at risk of the cancer coming back after nephrectomy for renal cell carcinoma (RCC) has not been successful. A recent study looked at a protein called kidney injury molecule-1 (KIM-1) in patients with RCC and whether this protein could be used to […]

read more

Anti-cancer vaccine ilixadencel plus sunitinib show promise for untreated metastatic kidney cancer

A phase 2 clinical trial with a new treatment called ilixadencel in combination with sunitinib has shown to improve overall survival in newly diagnosed patients with metastatic renal cell carcinoma (RCC). People given the combination treatment lived 10 months longer than those on sunitinib alone, suggesting that ilixadencel aids survival in these patients. Ilixadencel is […]

read more

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]

read more

ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

read more
Showing 1 to 10 of 149 results
  TOP